XLVS:LSE:LSE-Invesco Health Care S&P US Select Sector UCITS ETF (USD)

ETF | Others |

Last Closing

USD 728.65

Change

+14.95 (+2.09)%

Market Cap

N/A

Volume

3.17K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

+1.68 (+0.69%)

USD 292,109.69B
XNIF:LSE Xtrackers Nifty 50 Swap UCITS ..

-84.00 (-0.44%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

-4.00 (-1.88%)

USD 1,607.29B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.40 (+2.25%)

USD 701.81B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.18 (+1.26%)

USD 636.56B
0R1I:LSE NVIDIA Corp.

-3.30 (-2.70%)

USD 618.20B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.85 (+1.20%)

USD 266.08B
PRJU:LSE Amundi Index Solutions - Amund..

+0.67 (+2.23%)

USD 260.39B
0QZO:LSE 0QZO

+1.30 (+1.15%)

USD 258.54B

ETFs Containing XLVS:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.01% 85% B 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.01% 85% B 78% C+
Trailing 12 Months  
Capital Gain 4.06% 37% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.06% 32% F 43% F
Trailing 5 Years  
Capital Gain 63.28% 70% C- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.28% 67% D+ 75% C
Average Annual (5 Year Horizon)  
Capital Gain 10.61% 63% D 67% D+
Dividend Return 10.61% 62% D 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.66% 65% D 80% B-
Risk Adjusted Return 99.49% 87% B+ 93% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike